What is the effectiveness of cilostazol for preventing secondary stroke in patients with ischemic stroke related to small vessel disease?
Studies have shown that cilostazol is effective in reducing the risk of recurrent stroke in patients with noncardioembolic ischemic stroke, particularly in those with lacunar stroke in the subgroup analysis. The CSPS trial (Cilostazol for Prevention of Secondary Stroke) compared cilostazol with placebo in 1095 Japanese patients with noncardioembolic ischemic stroke and found a significant reduction in the risk of recurrent stroke in the cilostazol treatment group. 